Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 06, 2021 2:33pm
107 Views
Post# 33816875

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report CardI hope it plays out just as you have laid it out here: 

jfm1330 wrote: It is clear to me that the option of going for it alone is still the most likely option for the company, so to hold a KOL presentation on NASH makes sense. Also, even if they really want to partner, it is a good thing to keep the "alone" option clearly on the table. They will not give the NASH program for almost nothing. Also, as I said before, all this partnering thing is real, but at the same time it's a tactical way to gain time, waiting for the oncology results to come in. Add to that the ATM and you see that Levesque is giving himself as much tools as he can with all possibilities open. That being said, I still think that plan A is great results in oncology, sharp rise in the SP, raising money through the ATM, and going for it alone in NASH and assess the situation after 400 patients. That being said, I think they already know how things are shaping up in oncology. If it works, they should already see signs of efficacy.


<< Previous
Bullboard Posts
Next >>